ADAP

Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune's Phase 2 SPEARHEAD-1 Trial

Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows

First Preclinical Data from Adaptimmune's Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q1 2021 Results - Earnings Call Transcript

Adaptimmune Therapeutics PLC (ADAP) CEO Adrian Rawcliffe on Q4 2020 Results - Earnings Call Transcript

Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update